Results 251 to 260 of about 2,466,892 (329)

Neuroprotective Activity of 3-((6-(Phenylethynyl)pyridin-3-yl)oxy)quinuclidine: A Potential Ligand for the Treatment of Alzheimer's Disease. [PDF]

ACS Chem Neurosci
Cavagnero PS, Sánchez Y, Fell B, Ramírez Molina O, Gavilán J, Polo EA, Fuentealba J, Gutierrez M, Jiménez CA, López JJ.   +9 more
europepmc   +1 more source

Contingency management interventions for substance use and addictive behaviours: Review of the United Kingdom evidence base

Addiction, EarlyView.
Abstract Background and aims Substance use and other addictive behaviours including gambling remain major public health concerns in the UK. Despite the effectiveness of substance use treatment approaches, treatment adherence and success rates remain low.
Carol‐Ann Getty, Tricia McQuarrie, Eileen Brobbin   +2 more
wiley   +1 more source

Organophosphate Poisoning: Insights From a Case Report of Acute Cholinergic Syndrome. [PDF]

Clin Case Rep
Bereda G.
europepmc   +1 more source

The changing face of nicotine use in England: Age‐specific annual trends, 2014 to 2024

Addiction, EarlyView.
Abstract Aims To examine age‐specific trends in patterns of nicotine use in England between 2014 and 2024, including types of products used, exclusive and dual use of smoking and vaping, smoking frequency and the smoking history of those who vape.
Sarah E. Jackson, Lion Shahab, Vera Buss, Harry Tattan‐Birch, Sharon Cox, Eve Taylor, Jamie Brown   +6 more
wiley   +1 more source

Assessing species-specific neonicotinoid toxicity using cross-species chimeric nicotinic acetylcholine receptors in a Drosophila model. [PDF]

Sci Rep
Lassota A, Hodge JJL, Soller M.
europepmc   +1 more source

Motivational smoking cessation counselling and community‐based follow‐up after hospitalisation for vascular disease: A randomised controlled trial

Addiction, EarlyView.
Abstract Background and aims Evidence for motivational interviewing for smoking cessation is weak, with limited data on long‐term abstinence rates. This trial aimed to evaluate the effect of in‐hospital motivational interviewing‐based smoking cessation counselling combined with proactive referral to community‐based follow‐up on 6‐ and 12‐month ...
Karin Pleym, Elise Sverre, Harald Weedon‐Fekjær, Mohpal Singh Kahlon, Marie Stugaard, Einar Husebye, Serena Tonstad, Toril Dammen, John Munkhaugen   +8 more
wiley   +1 more source

Acetylcholine in the hippocampus: problems and achievements. [PDF]

Front Neural Circuits
Dobryakova YV, Bolshakov AP, Korotkova T, Rozov AV.   +3 more
europepmc   +1 more source

Rare but relevant: MDMA and hyponatraemia

Addiction, EarlyView.
Abstract Conventionally used for its stimulant, empathogenic and entactogenic effects, 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy) is one of the most commonly used psychoactive drugs, specifically among young adults and in nightlife and recreational party contexts.
Maria Rita Garcia, Nelson G. M. Gomes, Diana Dias‐da‐Silva   +2 more
wiley   +1 more source

The Biological and Prognostic Implications of the Nicotinic Acetylcholine Receptor α3, α5, and α7 Subunits in Oral Squamous Cell Carcinoma. [PDF]

Cancer Med
Lin CM, Lin LW, Chen TC, Ye YL, Chiang BL.   +4 more
europepmc   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source